Evidence map›Paper›PMID 38633861›Full record

ArticleInfectious diseases & clinical microbiology2023

Single-Dose Crossover Comparative Bioavailability Study of Two Different Posaconazole 100 mg Gastro-Resistant Tablets Under Fasted and Fed Conditions in Healthy Volunteers.

Nilden Dayan, Elif Oğralı, Cihan Kirişçioğlu, Udaya Kumar Dude, Recep Erşahin

Open access · hybridAbstract read
In one paragraph

Article in Infectious diseases & clinical microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Nilden DayanAbdi İbrahim Pharmaceuticals Inc., İstanbul, Türkiye.ORCID https://orcid.org/0000-0002-0476-7917
Elif OğralıAbdi İbrahim Pharmaceuticals Inc., İstanbul, Türkiye.ORCID https://orcid.org/0000-0002-7564-7840
Cihan KirişçioğluAbdi İbrahim Pharmaceuticals Inc., İstanbul, Türkiye.ORCID https://orcid.org/0000-0002-0100-9782
Udaya Kumar DudeAbdi İbrahim Pharmaceuticals Inc., İstanbul, Türkiye.ORCID https://orcid.org/0000-0003-3660-1951
Recep ErşahinAbdi İbrahim Pharmaceuticals Inc., İstanbul, Türkiye.ORCID https://orcid.org/0000-0003-2747-1964
Ağrı İbrahim Çeçen University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to compare the bioavailability of two different gastro-resistant oral tablet formulations of posaconazole under fasted and fed conditions and to evaluate a potential food effect on the bioavailability of each formulation. Materials and Methods: Healthy volunteers randomly assigned to receive a test product (Posagil Results: The bioequivalence criteria were met under fed conditions (T-fed vs. R-fed: geometric LSMean ratios of C Conclusions: Our findings suggest that the pharmacokinetic profile of Posagil

Indexed as

bioavailabilitybioequivalencegastro-resistant tabletNoxafil®PosaconazolePosagil®

Identifiers

PMID38633861
PMCPMC10986696
OpenAlexW4390604634

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.